Sanofi Completes Acquisition of Dynavax, Bolstering Adult Immunization Portfolio
SNY is trading near its 52-week low of $44.617 (9.1% above the low).
Summary
Sanofi has finalized its acquisition of Dynavax Technologies, integrating its adult hepatitis B vaccine HEPLISAV-B and a shingles vaccine candidate, significantly expanding Sanofi's presence in the adult immunization market.
Key Events · M&A and Partnerships · SNY
-
Acquisition Completed
Sanofi announced the completion of its acquisition of Dynavax Technologies Corporation, following the successful tender offer reported earlier today.
-
Strategic Portfolio Expansion
The acquisition includes Dynavax's adult hepatitis B vaccine HEPLISAV-B and a shingles vaccine candidate, enhancing Sanofi's adult immunization presence.
-
Dynavax Delisting
Dynavax common stock will cease to be traded on the NASDAQ Global Select Stock Market as of February 10, 2026, following the merger.
Analysis · SNY · Life Sciences
This 6-K confirms the definitive completion of Sanofi's acquisition of Dynavax Technologies, following the successful tender offer previously reported on the same day. The acquisition strategically enhances Sanofi's vaccine portfolio by adding HEPLISAV-B, an adult hepatitis B vaccine, and a promising shingles vaccine candidate. This move is expected to strengthen Sanofi's position in adult immunization, leveraging its global commercial reach for Dynavax's assets. The completion of the merger means Dynavax common stock will cease trading, marking the full integration of the company.
At the time of this filing, SNY was trading at $48.66 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $115.9B. The 52-week trading range was $44.62 to $60.12. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.